WO1994000587A2 - Attenuated equine herpesvirus-4 as live vaccine or recombinant vector - Google Patents
Attenuated equine herpesvirus-4 as live vaccine or recombinant vector Download PDFInfo
- Publication number
- WO1994000587A2 WO1994000587A2 PCT/GB1993/001355 GB9301355W WO9400587A2 WO 1994000587 A2 WO1994000587 A2 WO 1994000587A2 GB 9301355 W GB9301355 W GB 9301355W WO 9400587 A2 WO9400587 A2 WO 9400587A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- equine herpesvirus
- dna
- equine
- mutant
- herpesvirus
- Prior art date
Links
- 241000701089 Equid alphaherpesvirus 4 Species 0.000 title claims abstract description 130
- 229960005486 vaccine Drugs 0.000 title claims abstract description 19
- 239000013598 vector Substances 0.000 title claims description 17
- 230000002238 attenuated effect Effects 0.000 title abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 47
- 230000035772 mutation Effects 0.000 claims abstract description 10
- 108020004414 DNA Proteins 0.000 claims description 45
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 36
- 150000007523 nucleic acids Chemical group 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 102000053602 DNA Human genes 0.000 claims description 16
- 241000283073 Equus caballus Species 0.000 claims description 15
- 244000052769 pathogen Species 0.000 claims description 15
- 238000003780 insertion Methods 0.000 claims description 14
- 230000037431 insertion Effects 0.000 claims description 14
- 108020004511 Recombinant DNA Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 230000001717 pathogenic effect Effects 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 1
- 229940126580 vector vaccine Drugs 0.000 abstract description 3
- 239000013612 plasmid Substances 0.000 description 28
- 239000012634 fragment Substances 0.000 description 26
- 241000700605 Viruses Species 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 19
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 101150107933 RR-2 gene Proteins 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 101100413204 Homo sapiens RRM2 gene Proteins 0.000 description 7
- 101100357015 Suid herpesvirus 1 (strain Kaplan) RIR2 gene Proteins 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 101150056834 RR1 gene Proteins 0.000 description 6
- 102100026006 Ribonucleoside-diphosphate reductase subunit M2 Human genes 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 230000001018 virulence Effects 0.000 description 5
- 241000283086 Equidae Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101100195060 Homo sapiens RRM1 gene Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 102100036320 Ribonucleoside-diphosphate reductase large subunit Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 101100525035 Suid herpesvirus 1 (strain Kaplan) RIR1 gene Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 241000701081 Equid alphaherpesvirus 1 Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000724653 Borna disease virus Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000230501 Equine herpesvirus sp. Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000194048 Streptococcus equi Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- -1 pH 8.0) Chemical compound 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16741—Use of virus, viral particle or viral elements as a vector
- C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
Definitions
- the present invention is concerned with an Equine herpesvirus-4 mutant, a recombinant DNA molecule comprising Equine herpesvirus-4 DNA, a host cell transfected with said recombinant DNA molecule, a cell culture infected with the Equine herpesvirus-4 mutant, as well as a vaccine comprising such an Equine herpesvirus-4 mutant- Equine herpesviruses comprise a group of antigenically distinct biological agents which cause a variety of infections in the horse ranging from subclinical to fatal disease.
- Equine herpesvirus-4 is, like the distinct Equine herpesvirus-1, an alphaherpesvirus responsible for significant economic losses within the equine industry. Equine herpesvirus-4 is primarily associated with respiratory disease though Equine herpesvirus-4 induced abortions are occasionally reported.
- Equine herpesvirus-4 has been characterized as a double-stranded linear DNA molecule consisting of two covalently linked segments (L, 109 kbp; S, 35 kbp) the latter being flanked by inverted repeats.
- Equine herpesvirus-4 vaccines are available which are based on live Equine herpesvirus-4 viruses attenuated by serial passages of virulent strains in tissue culture.
- uncontrolled mutations are introduced into the viral genome, resulting in a population of virus particles heterogeneous in their virulence and immunizing properties.
- such traditional attenuated live virus vaccines can revert to virulence resulting in disease of the inoculated animals and the possible spread of the pathogen to other animals.
- a positive serological test is obtained for Equine herpesvirus-4 infection.
- Equine herpesvirus-4 vaccines it is not possible to determine by a (serological) test, e.g. an Elisa, whether a specific animal is a (latent) carrier of the virulent virus or is vaccinated. Furthermore, it would be advantageous if an Equine herpesvirus-4 strain could be used as a vaccine that affords protection against both Equine herpesvirus-4 infection and an other equine pathogen such as Equine herpesvirus-1.
- Equine herpesvirus-4 This could be achieved by inserting a gene encoding a relevant antigen of the equine pathogen into the genome of the Equine herpesvirus-4 in such a way that upon replication of the Equine herpesvirus-4 both Equine herpesvirus-4 antigens and the antigen of the other equine pathogen are expressed.
- WO 92/01045 discloses the DNA sequence of the thymidine kinase (T ) gene of Equine herpesvirus-4 and its use for the preparation of a vector vaccine. Glycoproteins gH and gC of Equine herpesvirus-4 and the genes coding for these proteins are described in WO 92/01057. These proteins are antigens which can be used as subunits in order to elicit a protective immune response against Equine herpesvirus-4 infection.
- T thymidine kinase
- Riggio et al. J. Virology 63, 1123-1133, 1989 disclose the DNA sequence of another glycoprotein, i.e. gB of Equine herpesvirus-4 which is involved in producing a protective immune response.
- Equine herpesvirus-4 mutant which can be used for the preparation of a vaccine against Equine herpesvirus-4 infection, the mutant viruses being attenuated in a controlled way in a manner which excludes the reversion to virulence and which still elicit a strong immune response in a host animal.
- such a mutant Equine herpesvirus-4 is characterized in that it comprises a mutation in the gene encoding a protein having the amino acid sequence shown in Fig. 6 resulting in the absence of the expression of said protein or in the expression of said protein in a non ⁇ functional form.
- Equine herpesvirus- 4 genome of the above region involved with the virulence of Equine herpesvirus-4, the approximate 5* and 3 1 ends of this region were not known, neither the nucleotide sequence nor the restriction sites within this region necessary to allow the introduction of controlled mutations were known, making the production of a genetic engineered attenuated Equine herpesvirus- 4 impossible.
- the gene encoding the protein involved with virulence was mapped within the about 18.5 kb BamHI A fragment and was further mainly localised within a region ranging from the Hindlll site at map position 2.7 to the Sail site at map position 5.5 within the BamHI A fragment ( Figure 1.).
- the exact nucleic acid sequence of this gene was determined and is shown in Fig. 5 from which restriction enzyme cleavage sites to be used for the genetic manipulation of the gene can be derived.
- the gene defined by the sequence of Fig. 5 encodes the enzyme ribonucleotide reductase (RR) and consists of about 3678 nucleotides.
- RR is composed of two non- identical subunits designated the large subunit (RR1) and the small subunit (RR2) .
- RR1 and RR2 are shown in Fig. 6 and correspond with the amino acid positions 1-789 and 1-320, respectively.
- the DNA sequences encoding the two subunits are shown in Fig. 5 and correspond with the nucleotide positions 77-2443 and 2435-3444, for RR1 and RR2 respectively.
- Equine herpesvirus-4 mutants comprising a mutation in such a related nucleic acid sequence are also included within the scope of the invention.
- mutation means any change introduced into the gene encoding the enzyme RR resulting in a mutated gene not capable of expressing a functional enzyme upon replication of the virus, e.g. as a result of a change of the tertiary structure of the altered enzyme or as a result of a shift of the reading frame.
- the presence or absence of RR enzyme activity can be assayed according to the method described by Darling et al. (1987) .
- the mutation may be an insertion, deletion and/or substitution of nucleotides in the gene encoding the enzyme.
- the Equine herpesvirus-4 mutants of the present invention preferably comprise a gene from which a fragment has been deleted so that no functional RR enzyme is produced upon replication of the virus.
- the deletion in the genome of the Equine herpesvirus-4 mutant may comprise the complete gene encoding the enzyme disclosed in Fig. 6.
- Equine herpesvirus-4 mutants according to the invention can also be obtained by inserting a nucleic acid sequence into the gene encoding the enzyme shown in Fig. 6 thereby preventing the expression of a functional enzyme.
- a nucleic acid sequence can inter alia be an oligonucleotide, for example of about 10-60 bp, preferably also containing one or more translational stop codons, or a gene encoding a polypeptide.
- Said nucleic acid sequence can be derived from any source, e.g. synthetic, viral, prokaryotic or eukaryotic. ⁇ "
- Equine herpesvirus-4 deletion mutants can contain above-mentioned nucleic acid sequence in place of the deleted Equine herpesvirus-4 DNA.
- a vector vaccine based on a safe live attenuated Equine herpesvirus-4 mutant offers the possibility to immunize against other pathogens by the expression of antigens of said pathogens within infected cells of the immunized host and can be obtained by inserting a heterologous nucleic acid sequence encoding a polypeptide heterologous to Equine herpesvirus-4 in an insertion- region of the Equine herpesvirus-4 genome.
- Equine herpesvirus-4 vector the prerequisite for a useful Equine herpesvirus-4 vector is that the heterologous nucleic acid sequence is incorporated in a permissive position or region of the genomic Equine herpesvirus-4 sequence, i.e. a position or region which can be used for the incorporation of a heterologous sequence without disrupting essential functions of Equine herpesvirus-4 such as those necessary for infection or replication.
- a permissive position or region of the genomic Equine herpesvirus-4 sequence i.e. a position or region which can be used for the incorporation of a heterologous sequence without disrupting essential functions of Equine herpesvirus-4 such as those necessary for infection or replication.
- Such a region is called an insertion- region.
- Equine herpesvirus-4 mutants which can be used as a viral vector, characterized in that said mutants comprise a heterologous nucleic acid sequence encoding a polypeptide inserted into the genome of Equine herpesvirus-4, the insertion-region being identified as the gene encoding the enzyme defined by the amino acid sequence shown in Fig. 6.
- Equine herpesvirus-4 insertion mutants as described above having a heterologous nucleic acid sequence inserted in place of deleted DNA representing the whole or a fragment of said gene are also within the scope of the present invention.
- Equine herpesvirus-4 insertion mutants comprises inter alia infective viruses which have been genetically modified by the incorporation into the virus genome of a heterologous nucleic acid sequence, i.e. a gene which codes for a protein or part thereof said gene being different of a gene naturally present in Equine herpesvirus-4.
- a heterologous nucleic acid sequence i.e. a gene which codes for a protein or part thereof said gene being different of a gene naturally present in Equine herpesvirus-4.
- polypeptide 1 refers to a molecular chain of amino acids with a biological activity, does not refer to a specific length of the product and if required can be modified in vivo or in vitro, for example by glycosylation, amidation, carboxylation or phosphorylation; thus inter alia peptides, oligopeptides and proteins are included within the definition of polypeptide.
- the heterologous nucleic acid sequence to be incorporated into the Equine herpesvirus-4 genome according to the present invention can be derived from any source, e.g. viral, prokaryotic, eukaryotic or synthetic.
- Said nucleic acid sequence can be derived from a pathogen, preferably an equine pathogen, which after insertion into the Equine herpesvirus-4 genome can be applied to induce immunity against disease.
- nucleic acid sequences derived from Equine herpesvirus-1 equine influenza virus, -rotavirus, - infectious anemia virus, arteritis virus, encephalitis virus, Borna disease virus of horses, Berue virus of horses, E.coli or Streptococcus equi are contemplated of for incorporation into the insertion-region of the Equine herpesvirus-4 genome.
- nucleic acid sequences encoding polypeptides for pharmaceutical or diagnostic application may be incorporated into said insertion-region.
- An essential requirement for the expression of the heterologous nucleic acid sequence in a Equine herpesvirus-4 mutant infected cell is an adequate promoter operably linked to the heterologous nucleic acid sequence. It is obvious to those skilled in the art that the choice of a promoter extends to any eukaryotic, prokaryotic or viral promoter capable of directing gene transcription in cells infected by the Equine herpesvirus-4 mutant, such as the SV-40 promoter (Science 222.
- a recombinant DNA molecule for recombination with Equine herpesvirus-4 DNA.
- a recombinant DNA molecule comprises vector DNA which may be derived from any suitable plasmid, cos id, virus or phage, plasmids being most preferred, and contains Equine herpes ⁇ virus-4 DNA of the insertion-region identified above, possibly having a nucleic acid sequence inserted therein if desired operably linked to expression control sequences.
- suitable cloning vectors are plasmid vectors such as pBR322, the various pUC and Bluescript plasmids, bacteriophages, e.g.
- Vectors to be used in the present invention are further outlined in the art, e.g. Rodriguez, R.L. and D.T. Denhardt, edit., Vectors: A survey of molecular cloning vectors and their uses, Butterworths, 1988.
- an Equine herpesvirus-4 DNA fragment comprising the insertion region identified above, is inserted into the cloning vector using well known recDNA techniques.
- Said DNA fragment may comprise essentially the complete DNA sequence of said gene shown in Fig. 5, and if desired flanking sequences thereof.
- Equine herpesvirus-4 deletion mutant is to be obtained at least part of said gene is deleted from the recombinant DNA molecule obtained from the first step.
- the heterologous nucleic acid sequence is inserted into the insertion-region present in the recombinant DNA molecule of the first step or in place of the DNA deleted from said recombinant DNA molecule prepared in the second step.
- the Equine herpesvirus-4 DNA sequences which flank the deleted DNA or the inserted nucleic acid sequence should be of appropriate length as to allow homologous recombination with the viral Equine herpesvirus-4 genome to occur.
- a construct can be made which contains two or more different inserted (heterologous) nucleic acid sequences derived from e.g.
- Equine herpesvirus-4 defined herein.
- Such a recombinant DNA molecule can be employed to produce an Equine herpesvirus-4 mutant which expresses two or more different antigenic polypeptides to provide a multivalent vaccine.
- cells for example rabbit cells, or equine cells, e.g. equine dermal cells, can be transfected with Equine herpesvirus-4 genomic DNA in the presence of the recombinant DNA molecule containing the deletion and/or insertion of (heterologous) nucleic acid sequence flanked by appropriate Equine herpesvirus-4 sequences whereby recombination occurs between the corresponding regions in the recombinant DNA molecule and the Equine herpesvirus-4 genome.
- equine cells e.g. equine dermal cells
- Recombination can also be brought about by transfecting Equine herpesvirus-4 genomic DNA containing host cells with a DNA fragment containing the (heterologous) nucleic acid sequence flanked by appropriate flanking insertion-region sequences without vector DNA sequences.
- Recombinant viral progeny is thereafter produced in cell culture and can be selected for example genotypically or phenotypically, e.g. by hybridization, detecting enzyme activity encoded by a gene co-integrated along with the (heterologous) nucleic acid sequence, screening for Equine herpesvirus-4 mutants which do not produce functional RR (Darling et al., 1987) or detecting the antigenic heterologous polypeptide expressed by the Equine herpesvirus-4 mutant immunologically.
- the selected Equine herpesvirus-4 mutant can be cultured on a large scale in cell culture whereafter Equine herpesvirus-4 mutant containing material or heterologous polypeptides expressed by said Equine herpesvirus-4 can be collected therefrom.
- mutant Equine herpesvirus-4 could be generated by cotransfection of several cosmids, containing between them the entire Equine herpesvirus- 4 genome, where an insertion and/or deletion has been engineered into the cos id possessing Equine herpesvirus-4 insertion region DNA.
- a live attenuated Equine herpesvirus-4 mutant which does not produce a functional RR, and if desired expresses one or more different heterologous polypeptides of specific equine pathogens can be used to vaccinate horses, susceptible to Equine herpesvirus-4 and these pathogens.
- Vaccination with such a live vaccine is preferably followed by replication of the Equine herpesvirus-4 mutant within the inoculated host, expressing in vivo Equine herpesvirus-4 polypeptides, and if desired heterologous polypeptides.
- An immune response will subsequently be elicited against Equine herpesvirus-4 and the heterologous polypeptides.
- An animal vaccinated with such an Equine herpesvirus-4 mutant will be immune for a certain period to subsequent infection of Equine herpesvirus-4 and above-mentioned pathogen(s) .
- An Equine herpesvirus-4 mutant according to the invention optionally containing and expressing one or more different heterologous polypeptides can serve as a monovalent or multivalent vaccine.
- An Equine herpesvirus-4 mutant according to the invention can also be used to prepare an inactivated vaccine.
- the Equine herpesvirus-4 mutant according to the presentation can be given inter alia by aerosol, spray, drinking water, orally, intradermally, subcutaneously or intra ⁇ muscularly.
- Ingredients such as skimmed milk or glycerol can be used to stabilise the virus. It is preferred to vaccinate horses by intranasal administration.
- a dose of 10 3 to 10 8 TCID 50 of the Equine herpesvirus-4 mutant per horse is recommended in general.
- This can be achieved by culturing cells infected with said Equine herpesvirus-4 mutant under conditions that promote expression of the heterologous polypeptide.
- the heterologous polypeptide may then be purified with conventional techniques to a certain extent depending on its intended use and processed further into a preparation with immunizing therapeutic or diagnostic activity.
- roller bottles of slightly sub-confluent monolayers of equine dermal cells (NBL-6) grown in Earle's Minimum Essential Medium (Flow) supplemented with 0,2% sodium bicarbonate, 1% non-essential amino acids, 1% glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin and 10% foetal calf serum were infected with virus of the Equine herpesvirus-4 strain 1942 at a .o.i. of 0,003 and allowed to adsor ⁇ for 60 in at 37 °C. They were incubated at 31 °C until extensive c.p.e. was evident and the majority of cells had detached from the bottle surface (2-6 days) .
- the infected cell medium was centrifuged at 5.000 r.p.m. for 5 min to pellet the cells, and the supernatant was centrifuged at 12.000 r.p.m. for 2 hours in a Sorvall GSA 6 X 200 ml rotor.
- the pellet was resuspended in 5 ml PBS, sonicated and centrifuged at 11.000 r.p.m. in a Sorvall SS34 rotor for 5 min to spin down cellular debris.
- Virus was then pelleted by centrifugation at 18.000 r.p.m. in a Sorvall SS34 rotor for 1 hour. Ratios of virus particles to plaque-forming units were approximately 1.000 to 5.000.
- the pelleted virus was resuspended in 10 ml NTE (NaCl/Tris/EDTA) and briefly sonicated. Contaminating cellular DNA was degraded by adding DNase at 10 ⁇ g/ml and incubating at 37 °C for 1 hour. SDS was added to a final concentration of 2%, and the preparation was extracted approximately 3 times with NTE equilibrated phenol until a clear interphase was obtained. A chloroform extraction was followed by ethanol precipitation of the DNA as described above. The DNA was pelleted, washed with 70% ethanol, resuspended in 10 ml of 100 mM NaCl and 10 ⁇ g/ml RNase and left overnight at room temperature.
- NTE NaCl/Tris/EDTA
- Equine herpesvirus-4 BamHI DNA fragments were ligated into the vector pUC9, a plasmid which includes the ampicillin-resistance gene from pBR322 and the polylinker region from M13mp9 (Vieira, J. and Messing,
- Equine herpesvirus-4 DNA BamHI-digested Equine herpesvirus-4 DNA were mixed in 50 mM Tris-HCl pH 7,5, 8 mM MgCl 2 , 10 mM dithiothreitol, 1 mM ATP in a final volume of 40 ⁇ l. 2 units of T4 DNA ligase (0,5 ⁇ l) were then added. The reaction was incubated at 4 °C for 16 hours.
- the vast majority of the RR sequence was obtained by sequencing the Equine herpesvirus-4 inserts in clones pl.7HindA and pBS1.3ESA, covering the region from the Hindlll site at 2.7 to the Sail site at 5.5.
- the sequence of the start of the RR1 gene was obtained by using intact Equine herpesvirus-4 BamHI A as a template; the end of the RR2 gene was sequenced using p4.2EcoA as a template.
- p4.2EcoA digestion of E ⁇ uine herpesvirus-4 BamHI A (contained in pUC9) with EcoRI and religation of the 6.9 kb fragment which contains the leftmost 4.2 kb of Equine herpesvirus-4 BamHI A attached to pUC9 vector.
- pl.7HindA derived from p4.2EcoA by digestion with Hindlll and religation of the 4.2 kb fragment, thereby deleting the 2.7 kb BamHI/Hindlll subfragment at the left end of p4.2EcoA and Equine herpesvirus-4 BamHI A.
- pBS1.3ESA 1.3 kb EcoRI/Sall subfragment of p4.2EcoA cloned between the EcoRI and Sail sites of Bluescript M13+ vector.
- Excised gel slices were transferred to Spin-X filter centrifuge tubes (Costar) , stored at -20 °C for 20 minutes and then centrifuged at 13000 rpm in a benchtop microcentrifuge for 30 minutes. The eluate was successively extracted with an equal volume of phenol (equilibrated with 1 M TrisHCl, pH 8.0), phenol/chloroform (1:1), chloroform and then ether and the DNA precipitated with two volumes of ethanol in the presence of 0.3 M sodium acetate (pH 6,0) at -70 °C for 30 minutes). DNA was pelleted by centrifugation, washed with 70% ethanol and dried in a vacuum dessicator. This precipitation procedure was repeated once more, the DNA finally resuspended in 20 to 50 ⁇ l of water and stored at -20 °C until required.
- phenol equilibrated with 1 M TrisHCl, pH 8.0
- phenol/chloroform (1:1) phenol/chloroform (1:
- Recombinant plasmid pBS1.3ESA was constructed by ligation of vector and insert DNA fragments as follows. 100 ng of vector DNA (Bluescript double- digested with EcoRI and Sail) was ligated to a three molar excess of insert DNA (1.3 kb EcoRI/Sall subfragment of Equine herpesvirus-4 BamHI A) using 3 units of T4 DNA ligase in the presence of 50 mM TrisHCl pH 7.6, 10 mM MgCl 2 , 1 mM ATP, 1 mM DTT, 5% w/v PEG-8000 (T4 DNA ligase buffer, BRL) , in a total volume of 30 ⁇ l at 14 "C for 16 to 20 hours.
- T4 DNA ligase buffer, BRL T4 DNA ligase buffer
- E.coli JM101 cells competent for DNA uptake were prepared by the calcium chloride method (Cohen et al., 1972) .
- each ligation reaction was added to 0.2 ml of competent E.coli cells prepared as described above, and incubated on ice for 30 minutes.
- This cell-DNA mixture was heat shocked by incubating at 37 "C for 5 minutes to facilitate entry of DNA into the bacterial cells.
- To the heat shocked mixture was added 1 ml of L broth and the bacteria were incubated at 37 ° C for 1.5 hours to allow expression of antibiotic resistance genes.
- Cells were spread onto five L agar plates (200 ml L broth, 3 g agar, sterilise by autoclaving) containing ampicillin at 100 ⁇ g/ml and plates were incubated for 15 minutes at room temperature to allow the liquid to be absorbed. Plates were inverted and incubated at 37 "C for 16 to 20 hours. Transformants appeared as separate and well- defined colonies on the surface of the agar plates.
- Transformants were screened for the presence of the desired recombinant plasmid by small scale isolation of plasmid DNA by the boiling method (Holmes and Quigley, 1981) .
- Equine herpesvirus-4 RR genes were located near the left terminus of this fragment ( Figure 1) .
- DNA was sequenced by the dideoxy chain termination method (Sanger et al., Proc. Natl. Acad. Sci. 7_4, 5463, 1977), using the double-stranded DNA sequencing technique in which single-stranded DNA template was produced by alkaline denaturation of plasmid DNA.
- DNA fragments to be sequenced were cloned into the Bluescript M13+ (1.3 kb EcoRI/Sall subfragment of BamHI A) or were already contained within pUC9 (1.5 kb Hindlll/EcoRI subfragment of BamHI A) .
- the enzyme kits used for sequencing was the T7 DNA polymerase kit obtained from Pharmacia.
- the DNA sequence of the RR genes and corresponding amino acid sequence are shown in Fig. 5 and Fig. 6.
- RR ribonucleotide reductase
- oligonucleotide adaptor AB (EcoRI-PstI ends) was cloned into the plasmid pBS2.3ESA, which contained most of the RR1 gene (bp 266-1632), cloned as a 1.3 kb Sall-EcoRI fragment into pBluescript M13+, to give plasmid pBSI.3AB.
- RRl gene (bp 266-1632) was cloned into vector pRIT2T to give plasmid pRIT1.3.
- oligonucleotide adaptor CD (EcoRI-Hindlll ends) was cloned into pRIT1.3 to give plasmid pRIT1.3CD.
- lacZ gene was cloned between the EcoRV and BamHI sites of pATRRl ⁇ /lRR2 ⁇ .
- Figure l Shows a restriction enzyme map of the Equine herpesvirus-4 genome and the location of the RR genes within the BamHI A restriction enzyme fragment of the Equine herpesvirus-4 genome.
- Figure 2 Represents the restriction enzyme maps of the recombinant plasmids p4.2EcoA, pl.7HindA and pBS1.3ESA.
- Figure 3 Represents the construction of the plasmid pATRRl " .
- Figure 4 Represents the construction of the plasmid pATRRl “ /RR2 " .
- Figure 5 Represents the nucleotide sequence of the RR gene of EHV-4.
- Figure 6 Represents the amino acid sequence of the enzyme ribonucleotide reductase of EHV-4.
- the enzyme consists of 2 subunits RRl and RR2.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention is concerned with an attenuated Equine herpesvirus-4 vaccine. The attenuation is achieved by a mutation into a gene of Equine herpesvirus-4 defined in SEQ ID NO: 1. The invention also relates to a vector vaccine comprising an Equine herpesvirus-4 mutant having a foreign gene inserted into the Equine herpesvirus-4 genome.
Description
ATTENUATED EQUINE HERPESVIRUS-4 AS LIVE VACCINE OR RECOMBINANT VECTOR
The present invention is concerned with an Equine herpesvirus-4 mutant, a recombinant DNA molecule comprising Equine herpesvirus-4 DNA, a host cell transfected with said recombinant DNA molecule, a cell culture infected with the Equine herpesvirus-4 mutant, as well as a vaccine comprising such an Equine herpesvirus-4 mutant- Equine herpesviruses comprise a group of antigenically distinct biological agents which cause a variety of infections in the horse ranging from subclinical to fatal disease.
Equine herpesvirus-4 is, like the distinct Equine herpesvirus-1, an alphaherpesvirus responsible for significant economic losses within the equine industry. Equine herpesvirus-4 is primarily associated with respiratory disease though Equine herpesvirus-4 induced abortions are occasionally reported.
The genome of Equine herpesvirus-4 has been characterized as a double-stranded linear DNA molecule consisting of two covalently linked segments (L, 109 kbp; S, 35 kbp) the latter being flanked by inverted repeats.
Control by vaccination of Equine herpesvirus-4 infection has been a long-sought goal.
Current vaccines comprise chemically inactivated virus vaccines and attenuated live virus vaccines.
However, inactivated vaccines generally induce only a low level of immunity, requiring additional immunizations, disadvantageously require adjuvants and are expensive to produce. Further, some infectious virus particles may survive the inactivation process and causes disease after administration to the animal. In general, attenuated live virus vaccines are preferred because they evoke a more long-lasting immune response (often both humoral and cellular) and are easier to produce.
Up to now only live attenuated, Equine herpesvirus-4 vaccines are available which are based on live Equine herpesvirus-4 viruses attenuated by serial passages of virulent strains in tissue culture. However, because of this treatment uncontrolled mutations are introduced into the viral genome, resulting in a population of virus particles heterogeneous in their virulence and immunizing properties. In addition it is well known that such traditional attenuated live virus vaccines can revert to virulence resulting in disease of the inoculated animals and the possible spread of the pathogen to other animals. Furthermore, with the existing live attenuated Equine herpesvirus-4 vaccines a positive serological test is obtained for Equine herpesvirus-4 infection. Thus, with the existing Equine herpesvirus-4 vaccines, it is not possible to determine by a (serological) test, e.g. an Elisa, whether a specific animal is a (latent) carrier of the virulent virus or is vaccinated.
Furthermore, it would be advantageous if an Equine herpesvirus-4 strain could be used as a vaccine that affords protection against both Equine herpesvirus-4 infection and an other equine pathogen such as Equine herpesvirus-1. This could be achieved by inserting a gene encoding a relevant antigen of the equine pathogen into the genome of the Equine herpesvirus-4 in such a way that upon replication of the Equine herpesvirus-4 both Equine herpesvirus-4 antigens and the antigen of the other equine pathogen are expressed.
Until now, the structure and functions of only a small number of genes within the about 144.000 base pairs genome of Equine herpesvirus-4 have been elucidated.
WO 92/01045 discloses the DNA sequence of the thymidine kinase (T ) gene of Equine herpesvirus-4 and its use for the preparation of a vector vaccine. Glycoproteins gH and gC of Equine herpesvirus-4 and the genes coding for these proteins are described in WO 92/01057. These proteins are antigens which can be used as subunits in order to elicit a protective immune response against Equine herpesvirus-4 infection.
Riggio et al. (J. Virology 63, 1123-1133, 1989) disclose the DNA sequence of another glycoprotein, i.e. gB of Equine herpesvirus-4 which is involved in producing a protective immune response.
It is an object of the present invention to provide an Equine herpesvirus-4 mutant which can be used for the preparation of a vaccine against Equine herpesvirus-4 infection, the mutant viruses being attenuated in a controlled way in a manner which excludes the reversion to virulence and which still elicit a strong immune response in a host animal.
According to the present invention such a mutant Equine herpesvirus-4 is characterized in that it comprises a mutation in the gene encoding a protein having the amino acid sequence shown in Fig. 6 resulting in the absence of the expression of said protein or in the expression of said protein in a non¬ functional form.
The development of techniques for controlled manipulation of genetic material has allowed the possibility of obtaining attenuated virus vaccines which avoid the disadvantages of the classic attenuated virus vaccines.
However, up to now no information was available with respect to the localisation on the Equine herpesvirus- 4 genome of the above region involved with the virulence of Equine herpesvirus-4, the approximate 5* and 31 ends of this region were not known, neither the nucleotide sequence nor the restriction sites within this region necessary to allow the introduction of controlled mutations were known, making the production of a genetic engineered attenuated Equine herpesvirus- 4 impossible.
The gene encoding the protein involved with virulence was mapped within the about 18.5 kb BamHI A fragment and was further mainly localised within a region ranging from the Hindlll site at map position 2.7 to the Sail site at map position 5.5 within the BamHI A fragment (Figure 1.).. The exact nucleic acid sequence of this gene was determined and is shown in Fig. 5 from which restriction enzyme cleavage sites to be used for the genetic manipulation of the gene can be derived.
The gene defined by the sequence of Fig. 5 encodes the enzyme ribonucleotide reductase (RR) and consists of about 3678 nucleotides. The enzyme reduces ribonucleot des to the corresponding deoxyribo- nucleotides and is essential for the formation of substrates for DNA synthesis in prokaryotic and eukaryotic systems. RR is composed of two non- identical subunits designated the large subunit (RR1) and the small subunit (RR2) .
The amino acid sequence of RR1 and RR2 are shown in Fig. 6 and correspond with the amino acid positions 1-789 and 1-320, respectively.
The DNA sequences encoding the two subunits are shown in Fig. 5 and correspond with the nucleotide positions 77-2443 and 2435-3444, for RR1 and RR2 respectively.
It will be understood that for the DNA sequence of the gene shown in Fig. 5 natural variations can exist between individual Equine herpesvirus-4 viruses. These variations may result in a change of one or more nucleotides in the RR gene' which, however still encodes for a functional enzyme. Moreover, the potential exists to use genetic engineering technology to bring about above-mentioned variations resulting in a DNA sequence related to the sequence shown in SEQ ID NO: 1. It is clear that Equine herpesvirus-4 mutants comprising a mutation in such a related nucleic acid sequence are also included within the scope of the invention.
The term "mutation" means any change introduced into the gene encoding the enzyme RR resulting in a mutated gene not capable of expressing a functional enzyme upon replication of the virus, e.g. as a result of a change of the tertiary structure of the altered enzyme or as a result of a shift of the reading frame.
The presence or absence of RR enzyme activity can be assayed according to the method described by Darling et al. (1987) .
The mutation may be an insertion, deletion and/or substitution of nucleotides in the gene encoding the enzyme.
The Equine herpesvirus-4 mutants of the present invention preferably comprise a gene from which a fragment has been deleted so that no functional RR enzyme is produced upon replication of the virus.
In another embodiment the deletion in the genome of the Equine herpesvirus-4 mutant may comprise the complete gene encoding the enzyme disclosed in Fig. 6.
Equine herpesvirus-4 mutants according to the invention can also be obtained by inserting a nucleic acid sequence into the gene encoding the enzyme shown in Fig. 6 thereby preventing the expression of a functional enzyme. Such a nucleic acid sequence can inter alia be an oligonucleotide, for example of about 10-60 bp, preferably also containing one or more translational stop codons, or a gene encoding a polypeptide. Said nucleic acid sequence can be derived from any source, e.g. synthetic, viral, prokaryotic or eukaryotic. ~"
In another embodiment of the present invention the Equine herpesvirus-4 deletion mutants can contain above-mentioned nucleic acid sequence in place of the deleted Equine herpesvirus-4 DNA.
It is another object of the present invention to provide a mutant Equine herpesvirus-4 which can be used not only for the preparation of a vaccine against Equine herpesvirus-4 infection but also against other equine infectious diseases. Such a vector vaccine based on a safe live attenuated Equine herpesvirus-4 mutant offers the possibility to immunize against other pathogens by the expression of antigens of said
pathogens within infected cells of the immunized host and can be obtained by inserting a heterologous nucleic acid sequence encoding a polypeptide heterologous to Equine herpesvirus-4 in an insertion- region of the Equine herpesvirus-4 genome.
However, _the prerequisite for a useful Equine herpesvirus-4 vector is that the heterologous nucleic acid sequence is incorporated in a permissive position or region of the genomic Equine herpesvirus-4 sequence, i.e. a position or region which can be used for the incorporation of a heterologous sequence without disrupting essential functions of Equine herpesvirus-4 such as those necessary for infection or replication. Such a region is called an insertion- region.
According to the present invention Equine herpesvirus-4 mutants are provided which can be used as a viral vector, characterized in that said mutants comprise a heterologous nucleic acid sequence encoding a polypeptide inserted into the genome of Equine herpesvirus-4, the insertion-region being identified as the gene encoding the enzyme defined by the amino acid sequence shown in Fig. 6.
Equine herpesvirus-4 insertion mutants as described above having a heterologous nucleic acid sequence inserted in place of deleted DNA representing the whole or a fragment of said gene are also within the scope of the present invention.
The term "Equine herpesvirus-4 insertion mutants" comprises inter alia infective viruses which have been genetically modified by the incorporation into the virus genome of a heterologous nucleic acid sequence, i.e. a gene which codes for a protein or part thereof said gene being different of a gene naturally present in Equine herpesvirus-4.
Upon infection of a cell by said Equine herpesvirus-4 insertion mutant it expresses the heterologous gene in the form of a heterologous polypeptide.
The term "polypeptide1' refers to a molecular chain of amino acids with a biological activity, does not refer to a specific length of the product and if required can be modified in vivo or in vitro, for example by glycosylation, amidation, carboxylation or phosphorylation; thus inter alia peptides, oligopeptides and proteins are included within the definition of polypeptide.
The heterologous nucleic acid sequence to be incorporated into the Equine herpesvirus-4 genome according to the present invention can be derived from any source, e.g. viral, prokaryotic, eukaryotic or synthetic. Said nucleic acid sequence can be derived from a pathogen, preferably an equine pathogen, which after insertion into the Equine herpesvirus-4 genome can be applied to induce immunity against disease. Preferably, nucleic acid sequences derived from Equine herpesvirus-1 , equine influenza virus, -rotavirus, - infectious anemia virus, arteritis virus, encephalitis virus, Borna disease virus of horses, Berue virus of horses, E.coli or Streptococcus equi are contemplated of for incorporation into the insertion-region of the Equine herpesvirus-4 genome.
Furthermore, nucleic acid sequences encoding polypeptides for pharmaceutical or diagnostic application, in particular immune modulators such as lymphokines," interferons or cytokines, may be incorporated into said insertion-region.
An essential requirement for the expression of the heterologous nucleic acid sequence in a Equine herpesvirus-4 mutant infected cell is an adequate promoter operably linked to the heterologous nucleic acid sequence. It is obvious to those skilled in the art that the choice of a promoter extends to any eukaryotic, prokaryotic or viral promoter capable of directing gene transcription in cells infected by the Equine herpesvirus-4 mutant, such as the SV-40 promoter (Science 222. 524-527, 1983) or, e.g., the metallothionein promoter (Nature 296, 39-42, 1982) or a heat shock promoter (Voellmy et al., Proc. Natl. Acad. Sci. USA 8_2, 4949-53, 1985) or the human cytomegalovirus IE promoter or promoters present in Equine herpesvirus-4.
Well-known procedures for inserting DNA sequences into a cloning vector and in vivo homologous recombination can be used to introduce a deletion and/or an insertion into the Equine herpesvirus-4 genome (Maniatis, T. et al. (1982) in "Molecular cloning", Cold Spring Harbor Laboratory; European Patent Application 74.808; Roizman, B. and Jenkins, F.J. (1985), Science 229, 1208; Higuchi, R. et al. (1988), Nucleic Acids Res. 16, 7351).
Briefly, this can be accomplished by constructing a recombinant DNA molecule for recombination with Equine herpesvirus-4 DNA. Such a recombinant DNA molecule comprises vector DNA which may be derived from any suitable plasmid, cos id, virus or phage, plasmids being most preferred, and contains Equine herpes¬ virus-4 DNA of the insertion-region identified above, possibly having a nucleic acid sequence inserted therein if desired operably linked to expression control sequences. Examples of suitable cloning vectors are plasmid vectors such as pBR322, the various pUC and Bluescript plasmids, bacteriophages, e.g. λgt-WES-λ B, charon 23 and the M13mp phages or
viral vectors such as SV40, Bovine papillomavirus, Polyoma and Adeno viruses. Vectors to be used in the present invention are further outlined in the art, e.g. Rodriguez, R.L. and D.T. Denhardt, edit., Vectors: A survey of molecular cloning vectors and their uses, Butterworths, 1988.
First, an Equine herpesvirus-4 DNA fragment comprising the insertion region identified above, is inserted into the cloning vector using well known recDNA techniques. Said DNA fragment may comprise essentially the complete DNA sequence of said gene shown in Fig. 5, and if desired flanking sequences thereof.
Second, if an Equine herpesvirus-4 deletion mutant is to be obtained at least part of said gene is deleted from the recombinant DNA molecule obtained from the first step.
This can be achieved for example by appropriate exonuclease III digestion or restriction enzyme treatment of the recombinant DNA molecule from the first step.
In the case an Equine herpesvirus-4 insertion mutant is to be obtained the heterologous nucleic acid sequence is inserted into the insertion-region present in the recombinant DNA molecule of the first step or in place of the DNA deleted from said recombinant DNA molecule prepared in the second step. The Equine herpesvirus-4 DNA sequences which flank the deleted DNA or the inserted nucleic acid sequence should be of appropriate length as to allow homologous recombination with the viral Equine herpesvirus-4 genome to occur.
If desired, a construct can be made which contains two or more different inserted (heterologous) nucleic acid sequences derived from e.g. different pathogens said sequences being flanked by insertion- region sequences of Equine herpesvirus-4 defined herein. Such a recombinant DNA molecule can be employed to produce an Equine herpesvirus-4 mutant which expresses two or more different antigenic polypeptides to provide a multivalent vaccine.
In order to obtain an Equine herpesvirus-4 mutant according to the invention, cells, for example rabbit cells, or equine cells, e.g. equine dermal cells, can be transfected with Equine herpesvirus-4 genomic DNA in the presence of the recombinant DNA molecule containing the deletion and/or insertion of (heterologous) nucleic acid sequence flanked by appropriate Equine herpesvirus-4 sequences whereby recombination occurs between the corresponding regions in the recombinant DNA molecule and the Equine herpesvirus-4 genome. Recombination can also be brought about by transfecting Equine herpesvirus-4 genomic DNA containing host cells with a DNA fragment containing the (heterologous) nucleic acid sequence flanked by appropriate flanking insertion-region sequences without vector DNA sequences. Recombinant viral progeny is thereafter produced in cell culture and can be selected for example genotypically or phenotypically, e.g. by hybridization, detecting enzyme activity encoded by a gene co-integrated along with the (heterologous) nucleic acid sequence, screening for Equine herpesvirus-4 mutants which do not produce functional RR (Darling et al., 1987) or detecting the antigenic heterologous polypeptide expressed by the Equine herpesvirus-4 mutant immunologically. The selected Equine herpesvirus-4 mutant can be cultured on a large scale in cell culture whereafter Equine herpesvirus-4 mutant
containing material or heterologous polypeptides expressed by said Equine herpesvirus-4 can be collected therefrom.
Alternatively, mutant Equine herpesvirus-4 could be generated by cotransfection of several cosmids, containing between them the entire Equine herpesvirus- 4 genome, where an insertion and/or deletion has been engineered into the cos id possessing Equine herpesvirus-4 insertion region DNA.
According to the present invention a live attenuated Equine herpesvirus-4 mutant which does not produce a functional RR, and if desired expresses one or more different heterologous polypeptides of specific equine pathogens can be used to vaccinate horses, susceptible to Equine herpesvirus-4 and these pathogens.
Vaccination with such a live vaccine is preferably followed by replication of the Equine herpesvirus-4 mutant within the inoculated host, expressing in vivo Equine herpesvirus-4 polypeptides, and if desired heterologous polypeptides. An immune response will subsequently be elicited against Equine herpesvirus-4 and the heterologous polypeptides. An animal vaccinated with such an Equine herpesvirus-4 mutant will be immune for a certain period to subsequent infection of Equine herpesvirus-4 and above-mentioned pathogen(s) .
An Equine herpesvirus-4 mutant according to the invention optionally containing and expressing one or more different heterologous polypeptides can serve as a monovalent or multivalent vaccine.
An Equine herpesvirus-4 mutant according to the invention can also be used to prepare an inactivated vaccine.
For administration to animals, the Equine herpesvirus-4 mutant according to the presentation can be given inter alia by aerosol, spray, drinking water, orally, intradermally, subcutaneously or intra¬ muscularly. Ingredients such as skimmed milk or glycerol can be used to stabilise the virus. It is preferred to vaccinate horses by intranasal administration. A dose of 103 to 108 TCID50 of the Equine herpesvirus-4 mutant per horse is recommended in general.
It is a further object of the present invention to produce subunit vaccines, pharmaceutical and diagnostic preparations comprising a heterologous polypeptide expressed by an Equine herpesvirus-4 mutant according to the invention. This can be achieved by culturing cells infected with said Equine herpesvirus-4 mutant under conditions that promote expression of the heterologous polypeptide. The heterologous polypeptide may then be purified with conventional techniques to a certain extent depending on its intended use and processed further into a preparation with immunizing therapeutic or diagnostic activity.
The above described active immunization against specific pathogens will be applied as a protective treatment in healthy animals. It goes without saying that animals already infected with a specific pathogen can be treated with antiserum comprising antibodies evoked by an Equine herpesvirus-4 mutant according to the invention. Antiserum directed against an Equine herpesvirus-4 mutant according to the invention can be prepared by immunizing animals with an effective amount of said Equine herpesvirus-4 mutant in order to elicit an appropriate immune response. Thereafter the animals are bled and antiserum can be prepared.
Example 1
Isolation and characterization of Equine herpesvirus-4 insertion region.
1. Culturinσ of Eσuine herpesvirus-4 virus
Roller bottles of slightly sub-confluent monolayers of equine dermal cells (NBL-6) grown in Earle's Minimum Essential Medium (Flow) supplemented with 0,2% sodium bicarbonate, 1% non-essential amino acids, 1% glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin and 10% foetal calf serum were infected with virus of the Equine herpesvirus-4 strain 1942 at a .o.i. of 0,003 and allowed to adsor ~for 60 in at 37 °C. They were incubated at 31 °C until extensive c.p.e. was evident and the majority of cells had detached from the bottle surface (2-6 days) . The infected cell medium was centrifuged at 5.000 r.p.m. for 5 min to pellet the cells, and the supernatant was centrifuged at 12.000 r.p.m. for 2 hours in a Sorvall GSA 6 X 200 ml rotor. The pellet was resuspended in 5 ml PBS, sonicated and centrifuged at 11.000 r.p.m. in a Sorvall SS34 rotor for 5 min to spin down cellular debris. Virus was then pelleted by centrifugation at 18.000 r.p.m. in a Sorvall SS34 rotor for 1 hour. Ratios of virus particles to plaque-forming units were approximately 1.000 to 5.000.
2. Preparation of Eσuine herpesvirus-4 DNA
The pelleted virus was resuspended in 10 ml NTE (NaCl/Tris/EDTA) and briefly sonicated. Contaminating cellular DNA was degraded by adding DNase at 10 μg/ml and incubating at 37 °C for 1 hour. SDS was added to a final concentration of 2%, and the preparation was extracted approximately 3 times with NTE equilibrated phenol until a clear interphase was obtained.
A chloroform extraction was followed by ethanol precipitation of the DNA as described above. The DNA was pelleted, washed with 70% ethanol, resuspended in 10 ml of 100 mM NaCl and 10 μg/ml RNase and left overnight at room temperature. Further purification was achieved by treatment with 1 mg/ml proteinase K for 2 hours at 31 °C. The DNA was extracted once with phenol:chloroform (1:1 vol/vol) , once with chloroform, ethanol precipitated, drained well and resuspended in 0.1 X SSC.
3. Cloninσ of Eσuine herpesvirus-4 DNA
Equine herpesvirus-4 BamHI DNA fragments were ligated into the vector pUC9, a plasmid which includes the ampicillin-resistance gene from pBR322 and the polylinker region from M13mp9 (Vieira, J. and Messing,
J. (1982) , Gene .19., 259) . 5 μg of Equine herpesvirus-4
DNA and 5 μg pUC9 DNA were separately digested with
BamHI.
Complete digestion was'verified by gel electrophoresis of aliquots of the reactions and then the DNA was extracted twice with an equal volume of phenol:chloroform (1:1) and ethanol-precipitated.
Ligation was performed essentially by the method of
Tanaka and Weisblu (J. Bact. 121. 354, 1975).
Approximately 0.1 μg of BamHI digested pUC9 and 1 μg of
BamHI-digested Equine herpesvirus-4 DNA were mixed in 50 mM Tris-HCl pH 7,5, 8 mM MgCl2, 10 mM dithiothreitol, 1 mM ATP in a final volume of 40 μl. 2 units of T4 DNA ligase (0,5 μl) were then added. The reaction was incubated at 4 °C for 16 hours.
Calcium-shocked E.coli DHI cells (Hanahan, D. (1983), J. Mol. Biol. 166. 557) were transformed with the recombinant plasmids essentially described by Cohen et al. (Proc. Natl. Acad. Sci., USA 69, 2110, 1972).
Three subclones of an Equine herpesvirus-4 clone containing the 13.5 kb BamHI A fragment (Figure 1) were constructed which contained the RR genes:- p4.2EcoA, pl.7HindA and pBS1.3ESA (Figure 2) . The vast majority of the RR sequence was obtained by sequencing the Equine herpesvirus-4 inserts in clones pl.7HindA and pBS1.3ESA, covering the region from the Hindlll site at 2.7 to the Sail site at 5.5. The sequence of the start of the RR1 gene was obtained by using intact Equine herpesvirus-4 BamHI A as a template; the end of the RR2 gene was sequenced using p4.2EcoA as a template. The clones were constructed as follows: p4.2EcoA: digestion of Eσuine herpesvirus-4 BamHI A (contained in pUC9) with EcoRI and religation of the 6.9 kb fragment which contains the leftmost 4.2 kb of Equine herpesvirus-4 BamHI A attached to pUC9 vector. pl.7HindA: derived from p4.2EcoA by digestion with Hindlll and religation of the 4.2 kb fragment, thereby deleting the 2.7 kb BamHI/Hindlll subfragment at the left end of p4.2EcoA and Equine herpesvirus-4 BamHI A. pBS1.3ESA: 1.3 kb EcoRI/Sall subfragment of p4.2EcoA cloned between the EcoRI and Sail sites of Bluescript M13+ vector.
The actual experimental procedures for cloning were as follows: i) Agarose Gel Electrophoresis
Agarose gel electrophoresis of DNA restriction fragments was carried out on horizontal 0.8% agarose gel slabs submerged in lxTBE buffer (0.09 M Tris, 0.09 M borate, 2 mM EDTA) . Gels were srained with ethidium bromide (1 μg/ml in water) for 30 minutes and destained for 30 minutes in water. DNA was visualised on a 302 nm UV transilluminator. ii) Purification of DNA Fragments From Agarose Gels
The desired DNA fragments were excised from the gel using a sterile scalpel. Excised gel slices were transferred to Spin-X filter centrifuge tubes (Costar) , stored at -20 °C for 20 minutes and then centrifuged at 13000 rpm in a benchtop microcentrifuge for 30 minutes. The eluate was successively extracted with an equal volume of phenol (equilibrated with 1 M TrisHCl, pH 8.0), phenol/chloroform (1:1), chloroform and then ether and the DNA precipitated with two volumes of ethanol in the presence of 0.3 M sodium acetate (pH 6,0) at -70 °C for 30 minutes). DNA was pelleted by centrifugation, washed with 70% ethanol and dried in a vacuum dessicator. This precipitation procedure was repeated once more, the DNA finally resuspended in 20 to 50 μl of water and stored at -20 °C until required.
iii) Ligation Reaction
Recombinant plasmid pBS1.3ESA was constructed by ligation of vector and insert DNA fragments as follows. 100 ng of vector DNA (Bluescript double- digested with EcoRI and Sail) was ligated to a three molar excess of insert DNA (1.3 kb EcoRI/Sall subfragment of Equine herpesvirus-4 BamHI A) using 3 units of T4 DNA ligase in the presence of 50 mM TrisHCl pH 7.6, 10 mM MgCl2, 1 mM ATP, 1 mM DTT, 5% w/v PEG-8000 (T4 DNA ligase buffer, BRL) , in a total volume of 30 μl at 14 "C for 16 to 20 hours. The construction of recombinant plasmids p4.2EcoA and pl.5HindA was accomplished by simple religation of 100 ng of the appropriate purified fragments mentioned previously.
iv) Transformation of Competent E.Coli Cells With Plasmid DNA
E.coli JM101 cells competent for DNA uptake were prepared by the calcium chloride method (Cohen et al., 1972) .
The contents of each ligation reaction were added to 0.2 ml of competent E.coli cells prepared as described above, and incubated on ice for 30 minutes. This cell-DNA mixture was heat shocked by incubating at 37 "C for 5 minutes to facilitate entry of DNA into the bacterial cells. To the heat shocked mixture was added 1 ml of L broth and the bacteria were incubated at 37 ° C for 1.5 hours to allow expression of antibiotic resistance genes. Cells were spread onto five L agar plates (200 ml L broth, 3 g agar, sterilise by autoclaving) containing ampicillin at 100 μg/ml and plates were incubated for 15 minutes at room temperature to allow the liquid to be absorbed. Plates were inverted and incubated at 37 "C for 16 to 20 hours. Transformants appeared as separate and well- defined colonies on the surface of the agar plates.
Transformants were screened for the presence of the desired recombinant plasmid by small scale isolation of plasmid DNA by the boiling method (Holmes and Quigley, 1981) .
The start and end points of the RR1 and RR2 genes was predicted by sequencing the ends of the Equine herpesvirus-4 DNA inserts in plasmids p4.2EcoA, pl.7HindA and pBS1.3ESA (Figure 1). Restriction mapping of Equine herpesvirus-4 BamHI A showed that the Equine herpesvirus-4 RR genes are located near the left terminus of this fragment (Figure 1) .
DNA was sequenced by the dideoxy chain termination method (Sanger et al., Proc. Natl. Acad. Sci. 7_4, 5463, 1977), using the double-stranded DNA sequencing technique in which single-stranded DNA template was produced by alkaline denaturation of plasmid DNA. DNA fragments to be sequenced were cloned into the Bluescript M13+ (1.3 kb EcoRI/Sall subfragment of BamHI A) or were already contained within pUC9 (1.5 kb Hindlll/EcoRI subfragment of BamHI A) . The enzyme kits used for sequencing was the T7 DNA polymerase kit obtained from Pharmacia. The DNA sequence of the RR genes and corresponding amino acid sequence are shown in Fig. 5 and Fig. 6.
Example 2
Construction of EHV-4 RR-neσative plasmids
Two ribonucleotide reductase (RR) negative plasmids were constructed for EHV-4.
1. RRl-neσative (Fiσ. 3)
A 0.9 kb Pstl - Hindlll fragment containing most of the RR2 gene (bp 2434-3357) was cloned into vector pIC20R to give plasmid pIC0.9PH.
An oligonucleotide adaptor AB(EcoRI-PstI ends) was cloned into the plasmid pBS2.3ESA, which contained most of the RR1 gene (bp 266-1632), cloned as a 1.3 kb Sall-EcoRI fragment into pBluescript M13+, to give plasmid pBSI.3AB.
An 1.4 kb Sall-Pstl fragment from pBSI.3AB containing most of the RRl-gene and oligonucleotide adaptor AB was cloned into pIC0.9PH to give plasmid pICRRl".
From this plasmid pICRRl" a 2.3 kb Sall-Hindlll fragment was cloned into pAT153 to give plasmid pATRRl". Finally the lacZ gene was cloned between the EcoRV and BamHI sites of pATRRl".
" RRl-neσative/RR2-neσative (Fig. 4)
An 1.3 kb Sall-EcoRI fragment containing most of the
RRl gene (bp 266-1632) was cloned into vector pRIT2T to give plasmid pRIT1.3.
An oligonucleotide adaptor CD (EcoRI-Hindlll ends) was cloned into pRIT1.3 to give plasmid pRIT1.3CD.
From plasmid pRIT1.3CD an 1.4 kb Hindlll fragment containing most of the RRl gene and the oligonucleotide adaptor CD was cloned into pAT153 to give plasmid pAT1.3CD.
An 1.9 kb Hindlll fragment containing the C-terminal
94 bp of the RR2 gene (bp 3351-3444) was cloned in ■ correct orientation into pAT1.3CD to give plasmid pATRRl"/RR2~.
Finally the lacZ gene was cloned between the EcoRV and BamHI sites of pATRRl ~/lRR2~ .
Legends
Figure l. Shows a restriction enzyme map of the Equine herpesvirus-4 genome and the location of the RR genes within the BamHI A restriction enzyme fragment of the Equine herpesvirus-4 genome.
Figure 2. Represents the restriction enzyme maps of the recombinant plasmids p4.2EcoA, pl.7HindA and pBS1.3ESA.
Figure 3. Represents the construction of the plasmid pATRRl".
Figure 4. Represents the construction of the plasmid pATRRl"/RR2".
Figure 5. Represents the nucleotide sequence of the RR gene of EHV-4.
Figure 6. Represents the amino acid sequence of the enzyme ribonucleotide reductase of EHV-4. The enzyme consists of 2 subunits RRl and RR2.
ADDITIONAL REFERENCES
Cohen, S.N., Chang, A.C.Y. and Hsu, L. (1972). Nonchromosomal antibiotic resistance in bacteria: genetic transformation of Escherichia coli by R-factor DNA. Proc. Natl. Acad. Sci. USA £9:2110.
Darling, A.J., Dutia, B.M. and Marsden, H.S. (1987). Improved method for the measurement of ribonucleotide reductase activity. J. Virological Methods 180:231-290.
Holmes, D.S. and Quigley, M. (1981) . A rapid boiling method for the preparation of bacterial plasmids. Anal. Biochem. 114:193-197.
Claims
1. An Equine herpesvirus-4 mutant comprising a mutation in the gene encoding a protein having the amino acid sequence shown in SEQ ID NO: 2.
2. An Equine herpesvirus-4 mutant according to claim 1, characterized in that the mutation is located within the DNA sequence shown in SEQ ID NO: 1.
3. An Equine herpesvirus-4 mutant according to claim 1 or 2, characterized in that the mutation is a deletion and/or insertion.
4. An Equine herpesvirus-4 mutant according to claim 3, characterized in that the insertion comprises a heterologous nucleic acid sequence encoding a polypeptide.
5. An Equine herpesvirus-4 mutant according to claim 4 characterized in that the heterologous nucleic acid sequence is under control of control sequences regulating the expression of the nucleic acid sequence in a cell infected with said Equine herpesvirus-4 mutant.
6. An Equine herpesvirus-4 mutant according to claim 5, characterized in that the heterologous nucleic acid sequence encodes an antigen of an equine pathogen.
7. Recombinant DNA molecule comprising vector DNA and at least part of the gene encoding the protein having the amino acid sequence shown in SEQ ID NO: 2.
8. Host cell transfected with the recombinant DNA molecule according to claim 7.
9. Cell culture infected with an Equine herpesvirus-4 mutant according to claims 1-6.
10.Vaccine comprising an Equine herpesvirus-4 mutant according to claims 1-6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9213882.5 | 1992-06-30 | ||
| GB929213882A GB9213882D0 (en) | 1992-06-30 | 1992-06-30 | Live modified equine herpesvirus-4 vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1994000587A2 true WO1994000587A2 (en) | 1994-01-06 |
| WO1994000587A3 WO1994000587A3 (en) | 1994-02-17 |
Family
ID=10717952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1993/001355 WO1994000587A2 (en) | 1992-06-30 | 1993-06-29 | Attenuated equine herpesvirus-4 as live vaccine or recombinant vector |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB9213882D0 (en) |
| WO (1) | WO1994000587A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0754226A1 (en) * | 1994-02-17 | 1997-01-22 | Syntro Corporation | Recombinant equine herpesviruses |
| WO1998027216A1 (en) * | 1996-12-14 | 1998-06-25 | The University Of Leeds | Ehv-1 vectors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8529880D0 (en) * | 1985-12-04 | 1986-01-15 | Medical Res Council | Polypeptide & pharmaceutical composition |
| AU629248B2 (en) * | 1988-09-13 | 1992-10-01 | Merial | Viral vaccines |
| FR2659349B1 (en) * | 1990-03-12 | 1993-12-24 | Rhone Merieux | RECOMBINANT HERPIC VIRUSES ESPECIALLY FOR THE PRODUCTION OF VACCINES, THEIR PREPARATION PROCESS, THE PLASMIDS MADE DURING THIS PROCESS AND THE VACCINES OBTAINED. |
| GB9014951D0 (en) * | 1990-07-06 | 1990-08-29 | Univ Glasgow | Equine herpesvirus-4 tk vaccine |
| DE4110962A1 (en) * | 1991-04-05 | 1992-10-08 | Bayer Ag | EQUINE HERPESVIREN (EHV) CONTAINING FOREIGN DNA, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN Vaccines |
-
1992
- 1992-06-30 GB GB929213882A patent/GB9213882D0/en active Pending
-
1993
- 1993-06-29 WO PCT/GB1993/001355 patent/WO1994000587A2/en active Application Filing
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5741696A (en) * | 1992-08-07 | 1998-04-21 | Syntro Corporation | Recombinant equine herpesviruses |
| EP0754226A1 (en) * | 1994-02-17 | 1997-01-22 | Syntro Corporation | Recombinant equine herpesviruses |
| EP0754226A4 (en) * | 1994-02-17 | 1999-02-24 | Syntro Corp | Recombinant equine herpesviruses |
| WO1998027216A1 (en) * | 1996-12-14 | 1998-06-25 | The University Of Leeds | Ehv-1 vectors |
| GB2335426A (en) * | 1996-12-14 | 1999-09-22 | Univ Leeds | EHV-1 Vectors |
| GB2335426B (en) * | 1996-12-14 | 2001-06-13 | Univ Leeds | EHV-1 Vectors |
| US6387685B1 (en) | 1996-12-14 | 2002-05-14 | The University Of Leeds | EHV-1 vectors |
| US6706515B2 (en) | 1996-12-14 | 2004-03-16 | Alexander Fred Markham | EHV-1 vectors |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1994000587A3 (en) | 1994-02-17 |
| GB9213882D0 (en) | 1992-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2031164C (en) | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof | |
| US6387376B1 (en) | Recombinant vaccine containing feline herpes virus type 1 particularly for treating feline infectious peritonitis | |
| EP0162738A1 (en) | Production of pseudorabies virus subunit vaccines | |
| WO1992001045A1 (en) | Equine herpesvirus-4 tk- vaccine | |
| EP0538341B1 (en) | Ehv-4 glycoprotein vaccine | |
| EP0510773B1 (en) | Canine coronavirus subunit vaccine | |
| EP0606437B1 (en) | Non-shedding live herpesvirus vaccine | |
| CA2099069C (en) | Recombinant feline herpesvirus vaccine | |
| EP0606452B1 (en) | Vector vaccines of recombinant feline herpesvirus | |
| US5674499A (en) | Equine herpesvirus gene 15 mutants | |
| EP0668355B1 (en) | Vaccine for the protection of horses against equine herpesvirus infection | |
| US5279965A (en) | Recombinant infectious laryngotracheitis virus | |
| WO1994000587A2 (en) | Attenuated equine herpesvirus-4 as live vaccine or recombinant vector | |
| US7309598B2 (en) | gM-negative EHV-mutants | |
| EP0663403A1 (en) | Vector vaccines of bovine herpesvirus I | |
| US5426051A (en) | Gene for A-type inclusion body of poxvirus | |
| US5674735A (en) | DNA encoding the EHV-4 gH or gC glycoprotein | |
| US6025181A (en) | Equine herpesvirus-4TK mutant | |
| US5874280A (en) | Vector vaccines of bovine herpesvirus I | |
| JP2002541815A (en) | Recombinant and mutant adenoviruses derived from bovine adenovirus type 1 | |
| JPH1028586A (en) | Non-essential region of avipoxvirus, recombinant avipoxvirus and vaccine using this region | |
| AU4384101A (en) | Polynucleotide vaccine formula for treating porcine respiratory and reproductive diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA GB JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA GB JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |